BRPI1007972A2 - composições de combinação e métodos para o tratamento de câncer - Google Patents

composições de combinação e métodos para o tratamento de câncer

Info

Publication number
BRPI1007972A2
BRPI1007972A2 BRPI1007972A BRPI1007972A BRPI1007972A2 BR PI1007972 A2 BRPI1007972 A2 BR PI1007972A2 BR PI1007972 A BRPI1007972 A BR PI1007972A BR PI1007972 A BRPI1007972 A BR PI1007972A BR PI1007972 A2 BRPI1007972 A2 BR PI1007972A2
Authority
BR
Brazil
Prior art keywords
methods
cancer treatment
combination compositions
compositions
combination
Prior art date
Application number
BRPI1007972A
Other languages
English (en)
Inventor
Dennis S France
Kenichi Ishil
Paolo Pucci
Thomas C K Chan
Original Assignee
Arqule Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc, Kyowa Hakko Kirin Co Ltd filed Critical Arqule Inc
Publication of BRPI1007972A2 publication Critical patent/BRPI1007972A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI1007972A 2009-02-12 2010-02-11 composições de combinação e métodos para o tratamento de câncer BRPI1007972A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15213809P 2009-02-12 2009-02-12
US17047109P 2009-04-17 2009-04-17
PCT/US2010/023893 WO2010093789A2 (en) 2009-02-12 2010-02-11 Combinational compositions and methods for treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI1007972A2 true BRPI1007972A2 (pt) 2016-09-13

Family

ID=42126095

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007972A BRPI1007972A2 (pt) 2009-02-12 2010-02-11 composições de combinação e métodos para o tratamento de câncer

Country Status (14)

Country Link
US (2) US20100297075A1 (pt)
EP (1) EP2396003B1 (pt)
JP (1) JP5687209B2 (pt)
KR (1) KR101620654B1 (pt)
CN (1) CN102481299B (pt)
AU (1) AU2010213696B2 (pt)
BR (1) BRPI1007972A2 (pt)
CA (1) CA2752232C (pt)
HK (1) HK1164159A1 (pt)
IL (1) IL214348A (pt)
MX (1) MX2011008584A (pt)
TW (1) TWI460178B (pt)
WO (1) WO2010093789A2 (pt)
ZA (1) ZA201105611B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481299B (zh) 2009-02-12 2015-02-25 艾科尔公司 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
WO2012003421A2 (en) 2010-07-01 2012-01-05 Arqule, Inc. Combinational compositions and methods for treatment of cancer
EP2611443A2 (en) 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer
WO2012082337A2 (en) * 2010-12-17 2012-06-21 Glaxo Wellcome Manufacturing Pte Ltd Combination
WO2012088491A2 (en) * 2010-12-23 2012-06-28 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
AU2012223528A1 (en) 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
US9180099B2 (en) 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CA2846630A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
AU2013252944B2 (en) * 2012-04-23 2017-04-13 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
CN102757435B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
PT3388420T (pt) * 2015-12-07 2022-09-20 Hinova Pharmaceuticals Inc Compostos de quinolina, método de preparação dos mesmos e uso dos mesmo como fármaco inibidor do transportador de urato
MA47516A (fr) 2017-02-15 2021-03-31 Taiho Pharmaceutical Co Ltd Composition pharmaceutique
CN108546244B (zh) * 2018-07-05 2021-04-23 南昌航空大学 一种3,3’-二吲哚乙烷类化合物的合成方法
WO2022150559A1 (en) * 2021-01-08 2022-07-14 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
CN102481299B (zh) 2009-02-12 2015-02-25 艾科尔公司 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
WO2012003421A2 (en) * 2010-07-01 2012-01-05 Arqule, Inc. Combinational compositions and methods for treatment of cancer
EP2611443A2 (en) * 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
MX2011008584A (es) 2012-01-27
CN102481299B (zh) 2015-02-25
CA2752232A1 (en) 2010-08-19
AU2010213696A1 (en) 2011-08-18
US9642847B2 (en) 2017-05-09
KR20110118817A (ko) 2011-11-01
EP2396003A2 (en) 2011-12-21
HK1164159A1 (en) 2012-09-21
WO2010093789A2 (en) 2010-08-19
IL214348A0 (en) 2011-09-27
EP2396003B1 (en) 2013-04-17
CA2752232C (en) 2016-11-22
WO2010093789A8 (en) 2011-03-17
TW201043626A (en) 2010-12-16
AU2010213696B2 (en) 2015-10-01
ZA201105611B (en) 2012-10-31
IL214348A (en) 2015-05-31
CN102481299A (zh) 2012-05-30
JP5687209B2 (ja) 2015-03-18
WO2010093789A3 (en) 2010-12-02
KR101620654B1 (ko) 2016-05-12
JP2012517477A (ja) 2012-08-02
US20150328208A1 (en) 2015-11-19
US20100297075A1 (en) 2010-11-25
TWI460178B (zh) 2014-11-11

Similar Documents

Publication Publication Date Title
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012005594A2 (pt) tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
IL218987A0 (en) Methods and compositions for treating cancer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EP2521913A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0815330A2 (pt) métodos e composições para tratar cânceres

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.